$NAUT

Nautilus Biotechnology, Inc.

CIK:0001808805|SEC Filings

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenue:
Total revenue	$ 190	$ 0	$ 190	$ 0
Cost of revenue:
Total cost of revenue	15	0	15	0
Operating expenses:
Research and development	9,613	10,394	19,320	21,930
Selling, general and administrative	6,325	6,703	12,742	14,011
Total operating expenses	15,938	17,097	32,062	35,941
Other income (expense):
Interest income	1,307	2,080	2,749	4,311
Other expense	(13)	(16)	(28)	(16)
Total other income	1,294	2,064	2,721	4,295
Net loss	$ (14,469)	$ (15,033)	$ (29,166)	$ (31,646)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.11)	$ (0.12)	$ (0.23)	$ (0.25)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.11)	$ (0.12)	$ (0.23)	$ (0.25)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)	127,135,738	126,204,632	126,886,646	126,174,603
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	127,135,738	126,204,632	126,886,646	126,174,603
Grant revenue
Revenue:
Total revenue	$ 180	$ 0	$ 180	$ 0
Service revenue
Revenue:
Total revenue	10	0	10	0
Cost of revenue:
Total cost of revenue	$ 15	$ 0	$ 15	$ 0

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities
Net loss	$ (29,166)	$ (31,646)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation	2,520	3,877
Amortization of operating lease right-of-use assets	2,154	2,336
Depreciation	606	922
Amortization (accretion) of premiums (discounts) on securities, net	(56)	(980)
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(953)	160
Accounts payable	(104)	(51)
Accrued expenses and other liabilities	376	390
Operating lease liabilities	(2,203)	(2,295)
Net cash used in operating activities	(26,826)	(27,287)
Cash flows from investing activities
Proceeds from maturities of securities	55,715	45,878
Purchases of securities	(28,496)	(11,278)
Purchases of property and equipment	(964)	(615)
Net cash provided by investing activities	26,255	33,985
Cash flows from financing activities
Proceeds from exercise of stock options	1,207	26
Proceeds from issuance of common stock under employee stock purchase plan	142	87
Net cash provided by financing activities	1,349	113
Net increase in cash, cash equivalents and restricted cash	778	6,811
Cash, cash equivalents and restricted cash at beginning of period	13,390	28,648
Cash, cash equivalents and restricted cash at end of period	14,168	35,459
Supplementary cash flow information on non-cash activities:
Acquisitions of property and equipment included in accounts payable	$ 355	$ 112

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 13,166	$ 12,388
Short-term investments	70,865	91,018
Prepaid expenses and other current assets	3,595	2,557
Total current assets	87,626	105,963
Property and equipment, net	3,999	3,457
Operating lease right-of-use assets	25,619	27,773
Long-term investments	45,155	52,739
Other long-term assets	1,177	1,180
Total assets	163,576	191,112
Current liabilities:
Accounts payable	1,095	943
Accrued expenses and other liabilities	3,553	3,177
Current portion of operating lease liabilities	3,991	3,832
Total current liabilities	8,639	7,952
Operating lease liabilities, net of current portion	23,825	26,187
Total liabilities	32,464	34,139
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 200,000,000 authorized as of June 30, 2026 and December 31, 2025; 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025	0	0
Common stock, $0.0001 par value, 1,000,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 127,224,640 and 126,469,610 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	13	13
Additional paid-in capital	492,616	488,737
Accumulated other comprehensive income (loss)	(331)	243
Accumulated deficit	(361,186)	(332,020)
Total stockholders’ equity	131,112	156,973
Total liabilities and stockholders’ equity	$ 163,576	$ 191,112